Pathophysiology of Volume Overload in Acute Heart Failure Syndromes

American Journal of Medicine

Volumn 119, Issue 12 SUPPL., 2006, Pages

  Chen, Horng H ^a   Schrier, Robert W ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Atrial natriuretic peptide; B type natriuretic peptide; Neurohormones; Pulmonary capillary wedge pressure; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; NEUROHORMONE;

ACUTE HEART FAILURE; ACUTE HEART FAILURE SYNDROME; ADRENERGIC SYSTEM; ARTICLE; BLOOD VOLUME; CARDIOVASCULAR RISK; FLUID RETENTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HORMONAL REGULATION; HUMAN; HYPERTENSION; LUNG CAPILLARY PRESSURE; LUNG CONGESTION; NATRIURESIS; PATIENT ASSESSMENT; PRESSORECEPTOR; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SODIUM RETENTION; SYMPATHETIC INNERVATION; VASOCONSTRICTION;

ACUTE DISEASE; ALDOSTERONE; ANGIOTENSINS; BLOOD VOLUME; HEART FAILURE; HUMANS; PULMONARY WEDGE PRESSURE; SYNDROME; WATER-ELECTROLYTE BALANCE;

EID: 33750958673     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.09.012     Document Type: Article

References (34)

1. Thom T., Haase N., Rosamond W., et al. Heart Disease and Stroke Statistics-2006 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. [published correction appears in Circulation. 2006;113:e696]. Circulation 113 (2006) e85-e151
2. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation 100 (1999) 999-1008
3. Schrier R.W. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 319 (1988) 1065-1072
4. Schrier R.W. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 319 (1988) 1127-1134
5. Schrier R.W. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 113 (1990) 155-159
6. Schrier R.W., and Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 341 (1999) 577-585
7. Schrier R.W., and Berl T. Nonosmolar factors affecting renal water excretion (first of two parts). N Engl J Med 292 (1975) 81-88
8. Schrier R.W., and Berl T. Nonosmolar factors affecting renal water excretion (second of two parts). N Engl J Med 292 (1975) 141-145
9. Szatalowicz V.L., Arnold P.E., Chaimovitz C., Bichet D., Berl T., and Schrier R.W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305 (1981) 263-266
10. Schrier R.W., Cadnapaphornchai M.A., and Umenishi F. Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonists. Heart Dis 3 (2001) 210-214
11. Schrier R.W. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?. J Am Coll Cardiol 47 (2006) 1-8
12. Gheorghiade M., Cody R.J., Francis G.S., McKenna W.J., Young J.B., and Bonow R.O. Current medical therapy for advanced heart failure. Am Heart J 135 pt 2 (1998) S231-S248
13. Chen H.H., Lainchbury J.G., Senni M., Bailey K.R., and Redfield M.M. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail 8 (2002) 279-287
14. Packer M. How should physicians view heart failure?. The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 71 (1993) 3C-11C
15. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [editorial]. J Am Coll Cardiol 20 (1992) 248-254
16. Unger T., and Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst 5 suppl 1 (2004) S7-S10
17. Mizuno Y., Yoshimura M., Yasue H., et al. Aldosterone production is activated in failing ventricle in humans. Circulation 103 (2001) 72-77
18. Maisel W.H., and Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91 (2003) 2D-8D
19. Mandinov L., Eberli F.R., Seiler C., and Hess O.M. Diastolic heart failure. Cardiovasc Res 45 (2000) 813-825
20. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 153 (1993) 937-942
21. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). [published correction appears in J Am Coll Cardiol. 2006;47:1503-1505]. J Am Coll Cardiol 46 (2005) e1-e82
22. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
23. Yoshimura M., Yasue K., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87 (1993) 464-469
24. Brunner-La Rocca H.P., Kaye D.M., Woods R.L., Hastings J., and Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 37 (2001) 1221-1227
25. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
26. Tonolo G., Richards A.M., Manunta P., et al. Low-dose infusion of atrial natriuretic factor in mild essential hypertension. Circulation 80 (1989) 893-902
27. Cao L., and Gardner D.G. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 25 (1995) 227-234
28. Itoh H., Pratt R.E., and Dzau V.J. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 86 (1990) 1690-1697
29. Boerrigter G., and Burnett Jr. J.C. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 13 (2004) 643-652
30. Rodeheffer R.J., Naruse M., Atkinson J.B., et al. Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation 88 (1993) 364-371
31. Cotter G., Moshkovitz Y., Milovanov O., et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail 4 (2002) 227-234
32. Shah M.R., Hasselblad V., Stinnett S.S., et al. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. J Card Fail 7 (2001) 105-113
33. Shah M.R., Hasselblad V., Stinnett S.S., et al. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. Eur J Heart Fail 4 (2002) 297-304
34. Lucas C., Johnson W., Hamilton M.A., et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 140 (2000) 840-847